- What: Gilead launched an innovative donation programme, donating its newly launched, patented, medicines sofosbuvir (Sovaldi®) and ledipasvir/sofosbuvir (Harvoni®). The programme includes universal screening, prevention, treatment and surveillance.
- Objective: It aims to develop a national hepatitis C prevention and control plan, in order to eliminate hepatitis C virus (HCV) in Georgia.
- Details: In 2015, Gilead provided 5,000 free courses of Sovaldi® to the government of Georgia and will provide 20,000 courses of Harvoni® each subsequent year.
- Scope: People living with hepatitis C in Georgia.
In 2015, Gilead launched a donation programme with the goal of eliminating HCV in Georgia. Through this programme, and together with the U.S. Centers for Disease Control (CDC), Gilead is assisting the government in building a national HCV elimination plan which includes universal screening, prevention activities, treatment, and surveillance. It aims to eliminate hepatitis C virus in Georgia.
In 2015, Gilead donated 5,000 free courses of Sovaldi® to the government of Georgia and will provide 20,000 courses of Harvoni® each subsequent year.
This programme is considered innovative in the Access to Medicine Index 2016 as it is the first donation programme of its kind in targeting hepatitis C virus with the aim of national elimination. In addition, Gilead donate newly launched, patented medicines in this programme (Sovaldi® and Harvoni®), whereas most structured donation programmes donate older, off-patent products.